Renaissance Technologies LLC decreased its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 39.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,582 shares of the company’s stock after selling 42,359 shares during the quarter. Renaissance Technologies LLC’s holdings in Unity Biotechnology were worth $87,000 at the end of the most recent quarter.
Analysts Set New Price Targets
Several research firms have issued reports on UBX. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Unity Biotechnology in a research note on Thursday, August 8th. Rodman & Renshaw assumed coverage on Unity Biotechnology in a research note on Thursday, August 22nd. They issued a “buy” rating and a $8.00 price objective for the company.
View Our Latest Stock Report on UBX
Unity Biotechnology Trading Down 2.7 %
Unity Biotechnology (NASDAQ:UBX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.15. On average, equities analysts predict that Unity Biotechnology, Inc. will post -1.49 earnings per share for the current year.
Unity Biotechnology Company Profile
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
See Also
- Five stocks we like better than Unity Biotechnology
- Best Stocks Under $10.00
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- What does consumer price index measure?
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Want to see what other hedge funds are holding UBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report).
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.